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TNF-induced necroptosis and the PARP pathway represent 
distinct and independent routes to programmed necrosis. 
First, DNA-alkylating agents such as 1-methyl-3-nitro-
1-nitrosoguanidine (MNNG) or methyl methanesulfonate 
rapidly activate the PARP pathway, whereas this is a late 
and secondary event in TNF-induced necroptosis. Second, 
inhibition of the PARP pathway does not protect against 
TNF-induced necroptosis, e.g., the PARP-1 inhibitor 3-AB 
prevented MNNG- but not TNF-induced adenosine-5′-
triposphate depletion, translocation of apoptosis-inducing 
factor, and necrosis. Likewise, olaparib, a more potent and 
selective PARP-1 inhibitor failed to block TNF-induced 
necroptosis, identical to knockdown/knockout of PARP-1, 
pharmacologic and genetic interference with c-Jun N-ter-
minal kinases and calpain/cathepsin proteases as further 
components of the PARP pathway. Third, interruption of 
TNF-induced necroptosis by interference with ceramide 
generation, RIP1 or RIP3 function or by the radical scaven-
ger butylated hydroxyanisole did not prevent programmed 
necrosis through the PARP pathway. In summary, our 
results suggest that the currently established role of the 
PARP pathway in TNF-induced necroptosis needs to be 
revised, with consequences for the design of future thera-
peutic strategies.
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Introduction
Programmed cell death (PCD) is essential for survival and 
homeostasis of multicellular organisms. Whereas induc-
tion of PCD through activation of caspases (subsequently 
termed “apoptosis”) represents the primary route to PCD 
Abstract Programmed necrosis is important in many 
(patho)physiological settings. For specific therapeutic 
intervention, however, a better knowledge is required 
whether necrosis occurs through one single “core pro-
gram” or through several independent pathways. Previ-
ously, the poly(ADP-ribose) polymerase (PARP) pathway 
has been suggested as a crucial element of tumor necrosis 
factor (TNF)-mediated necroptosis. Here, we show that 
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in most physiological settings, alternative forms of PCD 
have been discovered that operate without detectable cas-
pase activity. Of those, programmed necrosis represents 
the main mode of caspase-independent PCD [1]. Pro-
grammed necrosis can participate in vital processes when 
caspase-dependent pathways are abrogated, for example in 
the removal of interdigital webs during embryogenesis in 
Apaf-1-deficient embryos [2]. Furthermore, programmed 
necrosis contributes to the negative selection of lympho-
cytes, termination of immune responses, regulation of 
bone growth, ovulation, cellular turnover in the intestine 
or post-lactational regression of the mammary gland [2–4]. 
In addition, programmed necrosis has been implicated in 
the pathology of hyperacute shock [5], pancreatitis [6, 7], 
renal [8], cerebral and myocardial ischemia–reperfusion 
injury, epilepsy, muscular dystrophy, Alzheimer’s, Hun-
tington’s and Parkinson’s disease, as well as in the destruc-
tion of cells by pathogens such as HIV, vaccinia virus, Shi-
gella and Salmonella [1, 2, 9, 10]. As a backup mechanism, 
programmed necrosis can permit a cell to commit suicide 
if the caspase machinery fails or is inactivated (e.g., after 
virus infection or in apoptosis-resistant tumor cells) [2, 11].
Necroptosis represents a subset of programmed necro-
sis, which is elicited through death receptors and which 
depends on the activity of the protein kinases RIP1 and 
RIP3 [6, 7, 10, 11]. Downstream of RIP3, the very recently 
discovered proteins MLKL and PGAM5 further convey the 
necroptotic signal by inducing mitochondrial fragmentation 
[12]. Enzymes of the energy metabolism and production of 
reactive oxygen species (ROS), e.g., by the NADPH oxi-
dase Nox1 or by mitochondria, as well the deubiquitinase 
CYLD and the Bcl-2 family member Bmf represent further 
candidate mediators of necroptosis [1]. Moreover, FADD 
and caspase-8 constitute essential negative regulators of 
RIP1/RIP3-mediated necroptosis during normal embryonic 
development [11].
The two most extensively studied models of pro-
grammed necrosis are necroptosis initiated by the 55-kDa 
tumor necrosis factor (TNF) receptor (TNF-R1) and 
necrosis mediated via the poly(ADP-ribose) polymerase 
(PARP) pathway. The latter is initiated by overactivation 
of the DNA repair enzyme PARP-1, e.g., in response to 
DNA-alkylating agents such as 1-methyl-3-nitro-1-nitroso-
guanidine (MNNG), resulting in the massive synthesis of 
poly(ADP-ribose) (PAR) from nicotinamide adenine dinu-
cleotide (NAD+) and, in consequence, to the rapid deple-
tion of intracellular NAD+ and adenosine-5′-triposphate 
(ATP) pools. Subsequently, and involving c-Jun N-terminal 
kinases (JNK), the mitochondrial protein Bax and calpain/
cathepsin proteases, cleavage of apoptosis-inducing factor 
(AIF) occurs, which then translocates from mitochondria 
to the cytosol and further to the nucleus where it forms an 
active DNA-degrading complex with histone H2AX and 
cyclophilin A. This complex then induces caspase-inde-
pendent, large-scale DNA fragmentation and finally, necro-
sis [1, 13, 14].
A previous study has implicated the PARP pathway as 
an integral part of TNF-induced necroptosis in L929 fibro-
sarcoma cells [15]. Since the existence of one core program 
of necroptosis would allow a more efficient therapeutic 
interference than the existence of several distinct pathways 
that would have to be targeted simultaneously, this would 
also have implications for the future development of anti-
necrotic cytoprotective drugs [1].
We have previously demonstrated that the sphingolipid 
ceramide represents a key mediator of TNF-induced 
necroptosis in L929 cells as well as in other cell systems 
[16, 17]. In our efforts to more precisely define the targets 
of ceramide in TNF-induced necroptosis, we extended our 
investigations to components of the PARP pathway. Unex-
pectedly, our results indicate that the PARP pathway is not 
integral to TNF-induced necroptosis, but rather that both 
pathways represent distinct and independent routes to pro-
grammed necrosis.
Materials and methods
Reagents. Highly purified human recombinant TNF 
was provided by BASF Bioresearch (Ludwigshafen, 
Germany). Methyl methanesulfonate (MMS), cycloheximide 
(CHX), benzyloxycarbonyl-Phe-Ala-fluoromethylketone  
(zFA-fmk), trans-epoxysuccinyl-l-leucylamido(4-guan-
idino)butane (E-64), pepstatin A, imipramine and butyl-
ated hydroxyanisole (BHA) were purchased from Sigma 
(Deisenhofen, Germany), MNNG either from Sigma or 
from ABCR (Karlsruhe, Germany). Carbobenzoyl-l-leucyl-
l-leucyl-l-leucinal (MG-132) and poly(ADP-ribose) 
glycohydrolase (PARG) purified from bovine thymus were 
from Enzo (Lausen, Switzerland). 3-aminobenzamide 
(3-AB) and N-(5,6-dihydro-6-oxo-2-phenanthridinyl)-2-
acetamide hydrochloride (PJ-34) were obtained from TCI 
(Eschborn, Germany) and from Tocris (Ellisville, MO, 
USA), olaparib was purchased from Axon (Groningen, 
The Netherlands). Benzyloxycarbonyl-Val-Ala-Asp(OMe)-
fluoromethylketone (zVAD) was from Bachem (Buben-
dorf, Switzerland), JNK-inhibitor III and necrostatin-1 
were obtained from Merck (Darmstadt, Germany) and 
N-[l-3-trans-(propylcarbamoyl)-oxirane-2-carbonyl]-l-Ile-
l-Pro methyl ester (CA-074 Me) from Biomol (Hamburg, 
Germany).
Cell culture. L929ATCC, HeLa, wild-type Jurkat, 
HT-29, 293T, and MCF-7 cells were obtained from Ameri-
can Type Culture Collection (ATCC, Manassas, VA, USA). 
L929sA cells [18] were kindly provided by Peter Vande-
nabeele (Ghent, Belgium). L929Ts is a tumor necrosis 
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factor-related apoptosis-inducing ligand (TRAIL)-sensitive 
L929 subline derived in our laboratory [19]. Wild-type and 
PARP-1-deficient mouse embryonic fibroblasts (MEF) 
were kindly provided by Françoise Dantzer (Illkirch, 
France). RIP1-deficient Jurkat cells were a gift from Brian 
Seed (Boston, MA, USA). Wild-type and RIP1-deficient 
MEF have been previously described [20], as have NIH3T3 
cells naturally expressing or deficient for RIP3 [7]. NIH3T3 
transfectants stably expressing murine green-fluorescent-
protein (GFP) fusions to wild-type or kinase-defective 
murine RIP3 in the vector pEGFP-N1 (Takara, Mountain 
View, CA, USA) were generated by selection in DMEM 
medium containing 1 mg/ml G418 (PAA, Cölbe, Germany). 
Positive clones were identified by flow cytometry. Primary 
lung fibroblasts from JNK1-, JNK2-, and RIP3-deficient 
mice and their wild-type littermate controls were prepared 
and cultured as described [17]. Immortalized wild-type and 
JNK1/JNK2 double-deficient MEF were a kind gift from 
Roger Davis (Worcester, MA, USA). Wild-type, cathepsin 
D-deficient, and cathepsin D-deficient MEF stably trans-
fected with the pro-cathepsin D cDNA have been previ-
ously described [21], as have TNF-R1/R2 double-deficient 
mouse fibroblasts and their transfectants stably re-express-
ing TNF-R1 [22]. Wild-type and RIP3-deficient MEF were 
generated from d14.5 embryos according to standard pro-
cedures. Cells were cultivated in DMEM (NIH3T3, HeLa, 
MEF), McCoy’s (HT-29), RPMI 1640 (293T, MCF-7, 
TNF-R1/2 double-deficient mouse fibroblasts) or a mix-
ture of Click’s/RPMI 1640 medium (all other cell lines) 
supplemented with 10 % v/v calf serum and 10 mM glu-
tamine in a humidified incubator containing 5 % w/v 
CO2. Media were additionally supplemented with 1 mM 
sodium pyruvate (HT-29, 293T, MCF7) and 50 μg/ml 
each of streptomycin and penicillin (except for 293T and 
MCF-7 cells).
Immunoblots. Unless otherwise indicated, cells were 
harvested after treatment and lysed at 4 °C in TNE buffer 
(50 mM Tris pH 8.0, 1 % v/v NP40, 2 mM EDTA) contain-
ing 10 μg/ml pepstatin/aprotinin/leupeptin, 1 mM sodium 
orthovanadate and 5 mM NaF. AIF was detected in puri-
fied cytosolic fractions generated with the ProteoJET (Fer-
mentas, St. Leon-Rot, Germany) nuclear and cytoplasmic 
extraction kit. Identical amounts of cell protein per lane 
were resolved by electrophoresis on SDS polyacrylamide 
gels. After electrophoretic transfer to nitrocellulose, reac-
tive proteins were detected using antisera specific for 
actin (sc-1615, Santa Cruz, Heidelberg, Germany; A1978, 
Sigma), PARP-1 (556362, Becton–Dickinson, Heidelberg, 
Germany; 9542, Cell Signaling, Danvers, MA, USA), 
TRADD (3684, Cell Signaling), FADD (7B5, Enzo), 
Caspase-8 (4927, Cell Signaling), RIP1 (610458, Bec-
ton–Dickinson), PAR (551813, Becton–Dickinson), AIF 
(sc-13116, Santa Cruz), COXIV (sc-58348, Santa Cruz), 
histone (ab1791, Abcam, Cambridge, UK), JNK1 (554286, 
Becton–Dickinson), JNK2 (sc-271133, Santa Cruz), 
phospho-JNK (AF1205, R&D Systems, Wiesbaden, Ger-
many), TNF-R1 (sc-8436, Santa Cruz), human (PAB0287, 
Abnova, Heidelberg, Germany) or murine RIP3 (ADI-905-
242, Enzo), GFP (8369-1, Takara), and the ECL detection 
kit (GE Healthcare, Munich, Germany). Equal loading as 
well as efficiency of transfer was routinely verified for all 
Western blots by Ponceau S staining, and by reprobing the 
membranes for actin.
Quantitative real-time polymerase chain reaction (qRT-
PCR). Total RNA was isolated from L929Ts cells after 
induction of necroptosis with 100 ng/ml TNF for 0, 10, 15 
and 20 h using the High Pure RNA isolation kit (Roche, 
Mannheim, Germany) and transcribed into single-stranded 
cDNA using the 1st Strand cDNA Synthesis Kit for RT-PCR 
(AMV, Roche) following the recommendations of the man-
ufacturer. Quantification of PARP-1 expression levels was 
carried out with primers 5′-ATGCTACCACGCACAAC- 
3′ and 5′-CCAATCGGGTCTCCCT-3′ for murine PARP-1 
with murine glyceraldehyde 3-phosphate dehydroge-
nase (primers 5′-ACCACAGTCCATGCCATCAC-3′ and 
5′-TCCACCACCCTGTTGCTGTA-3′) as internal stand-
ard, using a LightCycler System, the LightCycler–FastStart 
DNA Master SYBR Green I Kit and LightCycler software 
version 3.5 (Roche).
Measurement of intracellular NAD+ and ATP levels. 
Cytosolic extracts were prepared in a buffer containing 
0.5 % v/v Triton X-100, 10 mM Tris pH 7.5, and 1 mM 
EDTA. For measurement of NAD+, identical amounts of 
protein were incubated for 30 min at 37 °C with 100 μl 
assay buffer (8 % v/v ethanol, 1 % w/v polyvinylpyrro-
lidone, 0.5 mM EGTA, 50 mM Tris/HCl pH 8.5, 1 mM 
phenazine ethosulfate, 0.44 mM 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide, 2 U alcohol dehy-
drogenase) before absorption was determined at 570 nm 
in a microplate reader (Tecan, Crailsheim, Germany). The 
cellular ATP content of the lysates was determined using 
a bioluminescence assay according to the manufacturer’s 
instructions (FL-AA, Sigma) in a FB-12 luminometer 
(Berthold, Bad Wildbad, Germany). Alternatively, intracel-
lular ATP levels were determined with the Cell Titer Glo 
Assay Kit (Promega, Mannheim, Germany).
Flow cytometric analysis of membrane integrity. Cells 
were seeded in 12-well plates at 5 × 104 cells/well. Fol-
lowing treatment, both detached and adherent cells were 
collected by centrifugation. The cells were resuspended in 
PBS/5 mM EDTA containing 2 μg/ml propidium iodide 
(PI), and the red fluorescence was measured on a FACS-
Calibur flow cytometer (Becton–Dickinson).
RNA interference. The validated siRNA specific for 
human PARP1 (ID # s1097), the predesigned siRNA spe-
cific for murine PARP-1 (ID # s62053), the custom-made 
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siRNA specific for murine RIP1 (target sequence 5′-CC 
ACUAGUCUGACUGAUG-3′), the predesigned siRNA 
specific for murine RIP3 (ID # s80755) as well as the nega-
tive control siRNA were obtained from Life Technolo-
gies, Darmstadt, Germany. L929Ts and Jurkat cells were 
transfected with 150 pmol siRNA by Amaxa nucleofection 
(Lonza, Cologne, Germany), using solution V and program 
X-001, and incubated for 72 h at 37 °C before further anal-
ysis. NIH3T3 cells naturally expressing RIP3 were trans-
fected as above, except for using solution R and program 
A-24, and incubation for 48 h.
Results
TNF and MNNG activate PARP-1, but with distinct 
kinetics
In L929 cells, TNF elicits PCD exclusively by necrop-
tosis but not by apoptosis [16, 17, 23]. Likewise, MNNG 
kills cells by necrosis rather than by apoptosis [14, 24]. 
Accordingly, three L929 cell lines available in our labora-
tory (TRAIL-sensitive L929Ts cells, “genuine” L929ATCC 
cells freshly obtained from ATCC and TNF-hypersensitive 
L929sA cells) did not display caspase activation or apop-
totic membrane blebbing after treatment with TNF or 
MNNG (unlike TNF/CHX-treated positive controls, Sup-
plementary Figure S1), confirming that in the L929 cell 
lines utilized for this study, both MNNG and TNF induce 
cell death through necrotic pathways rather than through 
caspase-dependent apoptosis.
During apoptosis, PARP-1 is inactivated by caspase-
3-mediated cleavage of the mature 116-kDa protein to an 
89-kDa product [16]. However, in L929Ts cells undergoing 
TNF-induced necroptosis, PARP-1 displays an atypical size 
shift/disappearance of the mature, uncleaved protein within 
20 h (Fig. 1a) [16, 19]. We have previously shown that cas-
pases are not responsible for this process [16]. This disap-
pearance is also not due to a general necroptotic destruction 
of cellular proteins, since TRADD, FADD, caspase-8, or 
RIP-1 did not show such changes in their levels (Fig. 1a). 
An PARP-1 antibody recognizing all cleavage fragments 
detected the apoptotic 89-kDa fragment in control extracts 
from L929Ts cells (Fig. 1b, Co), together with a pattern of 
additional bands. However, this pattern did not change in 
TNF-induced necroptosis (except for the disappearance of 
full-length PARP-1), and no additional cleavage products 
of PARP-1 were detected (Fig. 1b). Since we observed a 
time-dependent shift of the mature PARP-1 signal to higher 
molecular weights (Fig. 1a–g), we speculated that ubiquity-
lation [25] followed by complete proteasomal degradation 
might cause the disappearance of PARP-1. Treatment with 
the proteasome inhibitor MG-132 did not however prevent 
but rather accelerated the disappearance of the PARP-1 
signal (Fig. 1c). Similarly, we could rule out that a down-
regulation of PARP-1 at the transcriptional level is respon-
sible for its disappearance (Fig. 1d). Rather, in extracts 
from TNF-treated L929Ts cells, an antibody against PAR 
showed reactivity that co-migrated with the PARP-1 signal, 
and concurrently shifted to higher molecular weights in 
the course of necroptosis (Fig. 1e). Since the most promi-
nent target protein of PARP-1 poly(ADP-ribosyl)ation is 
PARP-1 itself [26], we hypothesized that the disappearance 
of the PARP-1 signal in Western blots during TNF-induced 
necroptosis was due to heavy poly(ADP-ribosyl)ation, 
rendering PARP-1 inaccessible for detection by PARP-1 
antibodies. Confirming our assumption, we could revert 
both disappearance and size shift as well as the associated 
poly(ADP-ribosyl)ation of PARP-1 by in vitro addition of 
PARG to cell lysates (Fig. 1f). Therefore, the disappear-
ance of the PARP-1 signal is an indicator of PARP-1 activa-
tion rather than PARP-1 destruction.
We confirmed the TNF-dependent activation/disappear-
ance of PARP-1 in time-course analyses not only in L929Ts 
but also in L929ATCC and L929sA cells (Fig. 1g). In the 
same three cell lines, the potent PARP1 activator MNNG 
[24] likewise induced the disappearance of PARP-1, how-
ever more rapidly, with changes already detectable within 
4–8 h after treatment (Fig. 1g). For TNF, this occurred at 
10 h of treatment or later, indicating that the initial steps 
of TNF-induced necroptosis do not require activation of 
PARP-1. Furthermore, in vitro addition of PARG reverted 
disappearance, size shift, and poly(ADP-ribosyl)ation of 
PARP-1 also in lysates from MNNG-treated L929Ts cells 
(Fig. 1h), confirming that the disappearance of PARP-1 in 
response to MNNG is likewise due to activation and auto-
poly(ADP-ribosyl)ation of PARP-1 itself (as independently 
reported previously [14, 27, 28]).
DNA-alkylating agents but not TNF cause rapid activation 
of the PARP pathway
In PARP-1-mediated necrosis, hyperactivation of PARP-1 
results in a rapid depletion of intracellular NAD+ [24]. 
Accordingly, MNNG and MMS, a distinct DNA-alkylating 
agent and activator of PARP-1 [29], uniformly induced a 
rapid decrease of intracellular NAD+ in all three L929 sub-
lines, leading to almost complete NAD+ depletion within 
2 h (Fig. 2a). In contrast, TNF failed to induce notable 
changes in NAD+ levels within this timeframe, but caused 
a decrease of NAD+ only at considerably later time points 
(8–48 h, Fig. 2a).
As a direct result of excessive NAD+ consumption by 
overactivated PARP-1, intracellular ATP is depleted by 
the cell’s efforts to resynthesize NAD+ [1]. In line, both 
MNNG and MMS caused the depletion of the intracellular 
335TNF and PARP-1 elicit distinct routes to necrosis
1 3
Fig. 1  PARP-1 is activated with distinct kinetics by TNF and MNNG. 
In (a–f), L929Ts cells were treated with 100 ng/ml TNF for the indi-
cated times. a Cells were analyzed for PARP-1 by immunoblotting with 
antibody 9542. The same lysates were additionally analyzed on sepa-
rate gels for TRADD, FADD, caspase-8, and RIP1. Arrows indicate 
the positions of the full-length proteins, which were additionally veri-
fied for TRADD, FADD, caspase-8, and RIP1 by parallel separation of 
lysates from 293T cells overexpressing the respective protein (293T+). 
Untransfected 293T cells (293T−) were included for control. Shifted 
signals for TRADD and RIP1 in these lanes represent the cross-reactive 
endogenous human proteins that differ in size from the endogenous 
murine proteins of L929Ts cells. b Western blot with antibody 9542 that 
detects all cleavage fragments of PARP-1. Arrows indicate the position 
of the full-length protein and the 89-kDa caspase-3 cleavage product 
present only in apoptotic control lysates (Co, extracts from cells treated 
with 100 ng/ml TNF and 2 μg/ml of the protein biosynthesis inhibitor 
CHX for 1 h). A longer exposure is shown for the lower part of the blot 
to increase the visibility of the reactive bands. c Cells were additionally 
treated with the proteasome inhibitor MG-132 (52.6 μM) as indicated. 
PARP-1 was detected with antibody 556362. d The expression levels 
of PARP-1 mRNA were determined by qRT-PCR in parallel to protein 
levels (shown below, PARP-1 was detected with antibody 9542). The 
expression of PARP-1 is shown relative to untreated cells. Comparable 
results were obtained with a different primer pair. e Following detec-
tion of PARP-1 (antibody 9542), the membrane was reprobed with an 
antibody for PAR to reveal the presence of poly(ADP-ribosyl)ated pro-
teins. f Lysates from cells treated with TNF for the indicated times were 
additionally incubated for the indicated times in the presence of 10 mM 
β-mercaptoethanol and 0.05 U PARG before PARP-1 was detected 
with antibody 9542 and reprobing of the membrane with an antibody 
for PAR. g L929Ts, L929ATCC, and L929sA cells were left untreated, 
treated with TNF as above, or treated with 0.5 mM MNNG for 15 min 
and further incubated with fresh medium without MNNG for the indi-
cated times before PARP-1 was detected with antibody 9542. h Lysates 
from L929Ts cells treated with MNNG as in (g) for the indicated times 
were incubated with PARG and analyzed as in (f). For all Western blot 
panels, detection of actin served as a loading control. For all figures, 
representative data from one out of at least two or more experiments 
with similar results are shown (n ≥ 2) and error bars indicate the stand-
ard deviations (SD) from at least triplicate determinations (n ≥ 3)
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ATP stores of L929Ts, L929ATCC, and L929sA cells 
within 4 h, whereas TNF again did not induce a notable 
reduction (Fig. 2b). This discrepancy between TNF and 
DNA-alkylating agents was further corroborated when we 
compared ATP levels with the progression of cell death. 
Both MNNG and TNF led to a pronounced reduction of 
membrane integrity in all three L929 cell lines. Whereas 
the rapid loss of intracellular ATP induced by MNNG 
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clearly preceded loss of membrane integrity, this occurred 
at later time points and concurrent with cell death for TNF 
(Fig. 2c).
Downstream of NAD+/ATP depletion, translocation of 
AIF from mitochondria to the cytosol and to the nucleus 
is essential in PARP-1-mediated necrosis [1, 28]. In con-
cordance with our above results, MNNG elicited a pro-
nounced translocation of AIF into the cytosol of L929Ts, 
L929ATCC and L929sA cells, whereas TNF caused only 
a marginal translocation of AIF in L929Ts and L929ATCC 
cells (more pronounced in TNF-hypersensitive L929sA 
cells), again occurring in the late to end rather than the 
early stages of cell death (24 h in L929Ts cells, 48 h in 
L929ATCC cells, 16 h in L929sA cells, Fig. 2d).
We additionally analyzed MNNG- and TNF-induced 
activation/disappearance of PARP-1, depletion of intracel-
lular ATP and loss of membrane integrity in human leu-
kemic Jurkat T cells and human HT-29 colorectal adeno-
carcinoma cells as two additional established cell systems 
for necroptosis [6, 17]. As shown in Fig. 2e, f, we obtained 
essentially the same results as with the three L929 sublines, 
confirming that the above findings are not limited to L929 
cells. In summary, individual components of the PARP 
pathway are activated only late in TNF-induced necropto-
sis (in contrast to their rapid activation by DNA-alkylating 
agents), most likely as a secondary consequence, but not 
the cause of necroptotic cellular disintegration.
Inhibition of the PARP pathway does not protect against 
TNF-induced necroptosis
To address the role of the PARP pathway in TNF-induced 
necroptosis in more detail, we analyzed the impact of phar-
macological inhibitors of PARP-1. The PARP-1 inhibitor 
3-AB [25, 26] impaired activation of PARP-1 (i.e., the dis-
appearance of the full-length PARP-1 signal) in all L929 
sublines in response to TNF and MNNG (Fig. 3a). How-
ever, while 3-AB impaired MNNG-induced ATP depletion 
and necrosis, TNF-induced loss of ATP and necroptosis 
were unaffected in all three L929 cell lines (Fig. 3b). Simi-
larly, the translocation of AIF into the cytosol of MNNG-
treated cells was blocked by 3-AB, whereas the late TNF-
induced AIF translocation remained unaltered in all L929 
sublines (Fig. 3c). Thus, the inhibition of PARP-1 by 3-AB 
is not causally linked to TNF-induced necroptosis, and 
therefore does not prevent the secondary loss of ATP and 
translocation of AIF that occur in the course of cellular 
disintegration.
We extended our investigations to Jurkat and HT-29 
cells, including murine NIH3T3 fibroblasts as a further 
cell systems for which TNF-induced necroptosis has been 
reported [7, 17]. In addition, we employed olaparib as a 
more potent and selective inhibitor of PARP-1 [26], and 
also the PARP-1 inhibitor PJ-34. As shown in Fig. 3d, 
all PARP-1 inhibitors (left panels) but not zVAD-fmk 
(right panel) effectively interfered with MNNG-induced 
necrosis. However, neither PARP-1 inhibitor reduced 
TNF(/zVAD/CHX)-induced necroptosis in any of the four 
cell lines (left panels). As the only exception, PJ-34 reduced 
TNF-mediated necroptosis in L929Ts cells. However, this 
was not observed in any of the other cell lines or with any 
of the other PARP-1 inhibitors and is therefore most likely 
due to unspecific activities that have been recently reported 
for PJ-34 [30, 31]. We obtained identical results after 
downregulation of PARP-1 in murine L929Ts and human 
Jurkat cells as well as in PARP-1-deficient MEF whereas 
MNNG-induced necrosis was clearly blocked (Fig. 3e).
JNK have been described as components of the PARP 
pathway required for mitochondrial dysfunction, AIF 
translocation, and necrosis [14]. However, pharmacologi-
cal inhibition of JNK did not affect TNF-induced necrop-
tosis in L929Ts cells, even at concentrations at which the 
inhibitor itself induced toxicity (Fig. 3f). In a direct genetic 
approach, neither primary lung fibroblasts from JNK1- or 
Fig. 2  DNA-alkylating agents but not TNF activate the PARP path-
way. a L929ATCC, L929Ts, and L929sA cells were stimulated with 
100 ng/ml TNF for the indicated times, or with 0.5 mM MNNG or 
25 mM MMS (as a distinct DNA-alkylating agent) for 15 min and 
subsequent incubation with fresh medium without MNNG/MMS for 
the indicated times. Subsequently, their intracellular NAD+ content 
was measured and is shown relative to untreated cells. b Cells were 
stimulated as in (a) and intracellular ATP levels were measured. c 
L929ATCC, L929Ts, and L929sA cells were stimulated with MNNG 
or TNF as in (a) and analyzed for intracellular ATP content and loss 
of membrane integrity (as a marker for cell death) at the indicated 
time points. Membrane integrity was measured by PI staining and 
flow cytometry. For clarity of presentation, the percentage of intact, 
large PI-negative cells that still retain their membrane integrity is 
shown. d Purified cytosolic fractions from L929Ts, L929ATCC, and 
L929sA cells were analyzed for translocation of AIF into the cytosol 
following stimulation with 100 ng/ml TNF for the indicated times or 
with 1 mM MNNG for 15 min and subsequent incubation with fresh 
medium without MNNG for 14 h. The purity of the fractions was ver-
ified by detection of actin (cytosolic marker), COXIV (mitochondrial 
marker) and histone (nuclear marker). Equal loading was verified by 
staining with Ponceau S (Supplementary Figure S2a), since actin dis-
played a decrease in these highly purified fractions during cell death. 
The activity of the employed COXIV and histone antibodies was 
confirmed with positive control lysates (Supplementary Figure S2d). 
e Jurkat and HT-29 cells were stimulated with MNNG as in (a) or 
100 ng/ml TNF with addition of 20 μM (HT-29) or 50 μM (Jurkat) of 
the broad-spectrum caspase inhibitor zVAD-fmk to prevent apoptosis 
and 2 μg/ml (Jurkat) or 5 μg/ml (HT-29) CHX to sensitize the cells 
[17]. Subsequently, PARP-1 was detected with antibody 9542. Detec-
tion of actin served as a loading control. f In parallel, the cells were 
analyzed for intracellular ATP content and loss of membrane integrity 
as in (c). For all flow cytometric analyses of membrane integrity, we 
measured the percentage out of a total of 10,000 analyzed cells that 
show loss of membrane integrity (this is calculated as 100 % minus 
the percentage of intact, large PI-negative cells to account for disin-
tegrated dead cells that have lost their PI staining again due to diffu-
sion)
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JNK2-deficient nor immortalized MEF from JNK1/JNK2 
double-deficient mice showed reduced sensitivities to TNF-
induced necroptosis relative to their respective wild-type 
littermate controls (Fig. 3g), dissimilar to the previously 
reported increased survival of JNK1−/− and JNK2−/− MEF 
in response to MNNG [14]. Furthermore, the RIP1 inhibi-
tor necrostatin-1 failed to inhibit TNF-induced JNK activa-
tion in L929Ts cells, although necroptosis in response to 
TNF was completely blocked (Fig. 3h). Therefore, JNK do 
not participate in TNF-induced necroptosis, in contrast to 
their reported function in the PARP pathway [14].
As further constituents of the PARP pathway, calpain and 
cathepsin proteases cleave AIF to initiate its mitochondrio-
nuclear translocation [13]. In TNF-induced necroptosis, cas-
pase inhibitors, such as the broad-spectrum caspase inhibitor 
zVAD, but not individual application of inhibitors for cal-
pain, cathepsin B, L, S, papain and cystein proteases poten-
tiate the death response [17, 19, 23]. Even when combined, 
the cathepsin B/L inhibitor zFA-fmk, the cathepsin B inhibi-
tor CA-074 Me and the broad-spectrum calpain/cysteine 
protease inhibitor E-64 failed to enhance TNF-induced 
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to protect from the enhanced necroptotic response elicited 
by TNF/zVAD (Fig. 3i), suggesting that calpains, cathepsins 
B and L and cysteine proteases neither positively nor nega-
tively participate in TNF-induced necroptosis. In controls, 
addition of zFA-fmk, E-64 and CA-074Me reduced MNNG-
induced necrosis whereas zVAD-fmk had no effect (Fig. 3i), 
confirming the reported role of calpains and cathepsins in 
the PARP pathway. Furthermore, pharmacological inhibi-
tion of cathepsin D by pepstatin A (Fig. 3j) or analysis of 
wild-type versus cathepsin D-deficient or cathepsin D-defi-
cient MEF ectopically re-expressing cathepsin D (Fig. 3k) 
revealed no differences in the necroptotic response to TNF, 
in summary demonstrating that despite their reported role in 
the PARP pathway, calpain and cathepsin proteases are not 
required for TNF-induced necroptosis. In control reactions, 
although pharmacological inhibition of cathepsin D indeed 
reduced MNNG-elicited necrosis in L929Ts, L929ATCC 
and L929sA cells (Fig. 3j), cathepsin D-deficient MEF were 
not protected from MNNG-induced necrosis in compari-
son to their wild-type counterparts or to cathepsin D-defi-
cient MEF ectopically re-expressing cathepsin D (Fig. 3k). 
These results suggest that pepstatin A is protective in the 
PARP pathway by targeting proteases other than cathepsin 
D and that cathepsin D plays no role in either TNF-induced 
necroptosis or the PARP pathway. Altogether, the above 
data suggest that TNF-induced necroptosis is not affected 
by inhibition of PARP-1 or subsequent components of the 
PARP pathway.
Interference with TNF-induced necroptosis does not block 
the PARP pathway
In a reverse approach, we examined whether interfer-
ence with known key mediators of TNF-induced necrop-
tosis also affected necrosis through the PARP pathway. 
The antidepressant imipramine prevents accumulation of 
Fig. 3  TNF-induced necroptosis is not blocked by inhibition of the PARP pathway. a L929Ts, L929ATCC, and L929sA cells were left untreated, 
treated with 100 ng/ml TNF for the indicated times, or treated with 1 mM MNNG for 15 min and further incubated for 16 h with fresh medium 
without MNNG in the presence or absence of the PARP inhibitor 3-AB (2.5 mM). Subsequently, activation/disappearance of PARP-1 was 
detected with antibody 9542. Detection of actin served as a loading control. b Cells were stimulated with TNF or with MNNG (0.5 mM) as in 
(a) before intracellular ATP levels were measured and loss of membrane integrity as a marker for cell death was determined by flow cytometry 
and PI staining. For clarity of presentation, the percentage of intact, large PI-negative cells with preserved membrane integrity is shown. c Cells 
were stimulated as in (a) with incubation for 14 h after MNNG treatment before purified cytosolic fractions were analyzed for translocation 
of AIF. The purity of the fractions was verified by detection of actin (cytosolic marker), COXIV (mitochondrial marker) and histone (nuclear 
marker). Equal loading was verified by staining with Ponceau S (Supplementary Figure S2b), since actin displayed a decrease in these highly 
purified fractions during cell death. At 48 h of TNF treatment, L929Ts cells additionally displayed a decrease of AIF, due to this very late stage 
of cell death. Nevertheless, 3-AB prevented both AIF translocation and actin decrease selectively in MNNG-, but not TNF-treated cells. d Left 
panels Necroptosis was induced in L929Ts, NIH3T3, Jurkat, and HT-29 cells in the absence or presence of the PARP1 inhibitors 3-AB (2.5 mM), 
olaparib (L929: 1 μM; NIH3T3, Jurkat: 50 nM; HT-29: 2 μM) or PJ-34 (20 μM) by treatment with 100 ng/ml TNF for 24 h (L929Ts, HT-29), 
16 h (NIH3T3) or 20 h (Jurkat) with addition of 20 μM (NIH3T3, HT-29) or 50 μM (Jurkat) zVAD-fmk and 2 μg/ml (Jurkat) or 5 μg/ml (HT-
29) CHX. In parallel, cells were treated with MNNG for 16 h as in (a) with or without addition of 3-AB, olaparib or PJ-34. Right panel to test 
whether or not zVAD-fmk inhibits MNNG-induced cell death, cells were treated with MNNG as in (a) in the absence or presence of 20 μM 
(Jurkat: 50 μM) zVAD-fmk. Subsequently, loss of membrane integrity was analyzed by flow cytometry. Lower panel To verify the efficacy of 
the inhibitors (in addition to their effect on MNNG-induced necrosis shown in the upper panels), activation/disappearance of PARP-1 in L929Ts 
cells treated with 100 ng/ml TNF for 24 h in the presence or absence of 2.5 mM 3-AB, 1 μM olaparib or 20 μM PJ-34 cells was detected with 
antibody 9542. Detection of actin served as a loading control. e L929Ts or Jurkat cells were nucleofected with an siRNA that does not elicit an 
RNA interference response (negative control) or with siRNA specific for murine or human PARP-1 (PARP-1 siRNA). Together with wild-type 
(WT) and PARP-1-deficient MEF, the cells were stimulated either with 0.5 mM MNNG for 15 min and further incubated for the indicated times 
with fresh medium without MNNG or with 100 ng/ml TNF in the absence (L929Ts) or presence (Jurkat, MEF) of 20 μM zVAD-fmk and 2 μg/
ml (Jurkat) or 1 μg/ml (MEF) CHX for 24 h before loss of membrane integrity was measured by PI staining and flow cytometry. Control Western 
blots for PARP-1 were performed to verify successful downregulation of endogenous murine or human PARP-1 or to show presence or absence 
of murine PARP-1. Detection of actin served as a loading control. f Inhibition of necroptosis by the JNK-inhibitory peptide JNK-inhibitor III was 
assayed in L929Ts cells treated with 100 ng/ml TNF for 16 h or not and increasing concentrations of JNK-inhibitor III. g Left panel Primary lung 
fibroblasts (LF) from wild-type (WT), JNK1-(JNK1−/−) and JNK2-deficient (JNK2−/−) mice or immortalized MEF from JNK1/JNK2 double-
deficient (JNK1/2−/−) mice were left untreated or incubated with 100 ng/ml TNF and 20 μM zVAD-fmk in the presence or absence of 2 μg/ml 
CHX to elicit necroptosis. After 18 h, loss of membrane integrity was analyzed by flow cytometry. Right panel Control Western blots were per-
formed to verify presence or absence of endogenous JNK1 and/or JNK2 and equal loading (actin). h L929Ts cells were stimulated with 100 ng/
ml TNF for the indicated times with or without the necroptosis inhibitor necrostatin-1 (Nec-1, 10 μM). Activation of JNK was analyzed by detec-
tion of phosphorylated p46 JNK1 and p54 JNK2 (arrows) in Western blots (left panel) using antibody AF1205. Detection of actin served as a 
loading control. To demonstrate the efficacy of the inhibitor, loss of membrane integrity of identically treated L929Ts cells was determined after 
24 h by flow cytometry (right panel). i L929Ts cells were incubated with 100 ng/ml TNF for 5 h or with MNNG (0.5 mM) as in (a) with optional 
addition of 20 μM zVAD-fmk and/or a combination of 20 μM each of zFA-fmk, E-64, and CA-074 Me before loss of membrane integrity was 
measured by flow cytometry. j L929Ts, L929ATCC and L929sA cells were preincubated for 24 h or not with the cathepsin D inhibitor pepstatin 
A (PepA, 100 μM) followed by either addition of 100 ng/ml TNF or not for 24 h, or by treatment with MNNG (0.5 mM) as in (a) or not. Subse-
quently, loss of membrane integrity was measured by flow cytometry. k Wild-type (WT), cathepsin D-deficient (CD−/−), and CD−/− MEF stably 
transfected with the pro-cathepsin D cDNA (CD−/−CatD) were incubated for 14 h with 100 ng/ml TNF in combination with 20 μM zVAD-fmk 
and 5 μg/ml CHX or with 1 mM MNNG for 30 min and further incubated for 16 h with fresh medium without MNNG before loss of membrane 
integrity was determined
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intracellular ceramide, a pivotal molecule in death recep-
tor-elicited necroptosis [16, 17, 19]. In L929sA cells, imi-
pramine impaired PARP-1 activation/disappearance, AIF 
translocation, cell death and the accompanying loss of 
ATP as late events in TNF-induced necroptosis but not in 
response to MNNG (Fig. 4a).
Fig. 3  continued
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Inhibition of RIP1 by necrostatin-1 clearly protected 
from TNF-induced necroptosis in all three L929 sublines, 
but had no effect on the course of MNNG-induced necrosis 
over 16 h (Fig. 4b). Likewise, TNF/zVAD/CHX-induced 
necroptosis was reduced by necrostatin-1 in both wild-
type and PARP-1-deficient MEF, whereas their differen-
tial response towards MNNG-induced necrosis remained 
completely unaffected (Fig. 4c). RIP1-deficient MEF were 
fully resistant to TNF/zVAD/CHX-induced necroptosis, 
but not noticeably protected from MNNG (Fig. 4d). Down-
regulation of RIP1 in NIH3T3 cells (that naturally express 
RIP3) [7], protected from TNF/zVAD-induced necroptosis, 
but not from MNNG (Fig. 4f). RIP1-deficient Jurkat cells 
proved fully resistant against TNF/zVAD/CHX-induced 
necroptosis, but, other than MEF and NIH3T3 cells, dis-
played a transient, statistically significant protection from 
MNNG, however not preventing final death (Fig. 4h). 
Absence or downregulation of RIP1 did not prevent the 
MNNG-induced rapid loss of intracellular ATP as an early 
step of the PARP pathway (Figs. 4e, g, i), in line with pre-
vious studies suggesting that RIP1 may also function in the 
PARP pathway, however at later stages [14, 27] rather than 
in the central, initial steps (as in TNF-induced necroptosis).
In line with the crucial function of RIP3 in necrop-
tosis [6, 7, 10], TNF(/zVAD/CHX) elicited necroptosis 
in L929Ts and NIH3T3 cells expressing RIP3, but not 
in 293T, MCF-7 and HeLa cells that lack endogenous 
RIP3 expression. In contrast, both MNNG and MMS 
uniformly induced necrosis in all cell lines (Fig. 4j). 
To exclude artifacts from these different constitutively 
RIP3-positive or -negative cell lines, we overexpressed 
wild-type or kinase-defective RIP3 in naturally RIP3-
deficient NIH3T3 cells [7] and downregulated RIP3 in 
NIH3T3 cells that naturally express RIP3 [7]. Similar 
to RIP1-deficient Jurkat cells (Fig. 4h), RIP3-deficient 
NIH3T3 cells displayed a statistically significant tran-
sient attenuation, but not protection from MNNG, while 
being fully resistant against TNF/zVAD-induced necrop-
tosis (Fig. 4k). Stable re-expression of wild-type, but 
not kinase-defective RIP3 restored full sensitivity to 
TNF/zVAD [6, 10]. In contrast, sensitivity for MNNG 
was restored by re-expression of both wild-type and 
kinase-defective RIP3, indicating that the kinase activ-
ity of RIP3 is not required for its function in the PARP 
pathway. In reverse, downregulation of RIP3 pro-
tected naturally RIP3-expressing NIH3T3 cells from 
TNF/zVAD-induced necroptosis while only transiently 
(but statistically significant) attenuating MNNG-induced 
necrosis (Fig. 4m). In primary MEF or primary lung 
fibroblasts from RIP3-deficient mice, TNF/zVAD/CHX-
induced necroptosis was completely blocked, whereas 
the course of MNNG-induced necrosis was not altered 
(Fig. 4o, q). As for RIP1, the rapid loss of ATP during 
MNNG-induced necrosis occurred identically in RIP3-
deficient, -downregulated or -retransfected cells (Fig. 4l, 
n, p, r), implicating that RIP3 also does not participate in 
the initial but later steps of the PARP pathway.
Consistent with the above studies [14, 27], our data sug-
gest a function of RIP1 in both TNF-induced necroptosis 
and MNNG-mediated necrosis. However, while RIP1 is 
clearly crucial for TNF-induced necroptosis in a cell type-
independent manner, its contribution to MNNG-induced 
necrosis appears to be of more limited importance and cell 
type-specific. Although previously not investigated, our 
data indicate that the same is also true for RIP3. Notably, 
Xu et al. [14] have previously ruled out that the function 
of RIP1 in MNNG-induced necrosis depends on the TNF 
signaling pathway by demonstrating that MEF deficient for 
TNF-R1 remain as sensitive to MNNG as wild-type MEF. 
We extended this experiment by showing that the course 
of MNNG-induced necrosis was identical in both TNF-
R1/TNF-R2 double-deficient fibroblasts and TNF-R1/TNF-
R2 double-deficient control fibroblasts that ectopically re-
express TNF-R1, thus clearly demonstrating that any role 
of RIP1 or RIP3 in the PARP pathway cannot depend on 
signals mediated by TNF-R1 (Fig. 4s). In combination with 
the kinase-independent function of RIP3 in the PARP path-
way (contrasting TNF-dependent necroptosis), our results 
demonstrate that although RIP1 and RIP3 participate in 
both TNF-induced necroptosis and the PARP pathway, 
their functions in each pathway are independent and do not 
connect the two pathways.
Finally, scavengers of ROS such as BHA can protect 
L929 cells from TNF-induced necroptosis [17, 23]. Cor-
respondingly, BHA decreased necroptosis in TNF-treated 
L929Ts, L929ATCC and L929sA cells, but failed to protect 
against necrosis induced by MNNG and MMS in any of the 
three cell lines (Fig. 4t).
In contrast to the results obtained here, a previous study 
has suggested an important role of the PARP pathway in 
TNF-induced necroptosis of L929 cells [15]. We there-
fore replicated the key experiments of the above study 
(protective effects of the PARP-1 inhibitor 3-AB against 
TNF- or TNF/zVAD-induced necroptosis and against loss 
of intracellular ATP) under exactly the same experimen-
tal conditions for L929Ts, L929ATCC and L929sA cells. 
Fully consistent with our above findings, 3-AB did not pre-
vent necroptosis measured by loss of membrane integrity 
(Fig. 5a) or by loss of ATP (Fig. 5b) in any of the three 
cell lines (but effectively interfered with MNNG-induced 
necrosis in controls, Fig. 5c). As a likely explanation, Los 
et al. utilized a single transfectant clone of L929 cells sta-
bly expressing CD95 (L929-APO-1-6) for their experi-
ments [15, 32], which may show altered responses in com-
parison to the parental, untransfected L929 cells lines used 
in this study.
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Discussion
In this study, we present evidence that TNF-induced 
necroptosis and the PARP pathway represent two distinct 
and independent routes to programmed necrosis. The 
importance of programmed necrosis, especially in patho-
logical situations, becomes increasingly obvious and the 
possibility for therapeutic suppression of necrosis has 
raised great expectations [1]. A role in the pathology of 
diseases has been reported for both necroptosis and PARP-
1-dependent necrosis. Inhibition of necroptosis by target-
ing RIP1 effectively reduced renal [8], cardiac and retinal 
ischemia/reperfusion injury [1], limited brain damage, and 
improved motor and cognitive performance in mouse mod-
els [1]. Similarly, genetic deficiency for RIP3 limited tis-
sue damage in a pancreatitis model [1]. PARP-1-dependent 
necrosis plays a central role in inflammatory responses in 
cells of the central nervous, cardiovascular, and immune 
systems. PARP-1 inhibitors have been effective in the 
treatment of ischemia/reperfusion damage after stroke or 
brain, myocardial, hepatic, and renal ischemia/reperfusion 
injury, other acute forms of cardiomyopathies and heart 
failure, tissue injury in response to septic and hemorrhagic 
shock, as well as acute lung inflammation, peritonitis, and 
Fig. 4  The PARP pathway is not blocked by interference with key mediators of TNF-induced necroptosis. a In the presence or absence of 
25 μM imipramine, L929sA cells were stimulated with 100 ng/ml TNF for 0 or 16 h. Alternatively, the cells were treated with 1 mM MNNG for 
15 min and further incubated with fresh medium without MNNG for the indicated times. PARP-1 was detected in Western blots with antibody 
9542. Detection of actin served as a loading control. The asterisk indicates a nonspecific band. In parallel, nuclear translocation of AIF was deter-
mined using purified cytosolic nuclear fractions from the same experiment. Actin (cytosolic marker), COXIV (mitochondrial marker) and histone 
(nuclear marker) were used to control fractionation quality. Equal loading was verified by staining with Ponceau S (Supplementary Figure S2c), 
since actin displayed a decrease in these highly purified fractions during cell death. Imipramine selectively prevented this decrease as well as AIF 
translocation and activation/disappearance of PARP-1 in TNF-, but not MNNG-treated cells. In addition, intracellular ATP levels were measured 
and loss of membrane integrity was determined by flow cytometry and PI staining. For clarity of presentation, the percentage of intact, large 
PI-negative cells with preserved membrane integrity is shown. b L929Ts, L929ATCC and L929sA cells were treated with 100 ng/ml TNF for 
24 h or with 0.5 mM MNNG for 15 min and further incubated for the indicated times with fresh medium without MNNG in the presence of the 
indicated concentrations of the RIP1 inhibitor necrostatin-1. Following stimulation, loss of membrane integrity was analyzed by flow cytometry. 
Necrostatin-1 clearly protected from TNF-induced necroptosis in all three L929 sublines at 20 μM, but not from MNNG-induced necrosis, even 
at a concentration of 50 μM. c Wild-type (WT) and PARP-1-deficient MEF were stimulated either with 0.5 mM MNNG for 15 min and further 
incubated with fresh medium without MNNG or with 100 ng/ml TNF, 20 μM zVAD-fmk and 2 μg/ml CHX in the presence or absence of 50 μM 
necrostatin-1 (Nec-1) for 24 h before loss of membrane integrity was measured by PI staining and flow cytometry. Necrostatin-1 reduced the 
TNF/zVAD/CHX-induced death of both wild-type and PARP-1-deficient MEF, indicating that TNF/zVAD/CHX indeed elicits necroptosis in 
these cells. d Wild-type (WT) and RIP1-deficient (RIP1−/−) MEF were stimulated for the indicated times with MNNG as in (b) or with 100 ng/
ml TNF in combination with 20 μM zVAD-fmk and 2 μg/ml CHX before loss of membrane integrity was measured by flow cytometry. Inset 
control Western blot for murine RIP1 or actin to verify presence or absence of endogenous murine RIP1 and equal loading. e Intracellular ATP 
levels were analyzed from the same cells stimulated with MNNG for the indicated times as in (b). f, g NIH3T3 cells naturally expressing RIP3 
were nucleofected with an siRNA that does not elicit an RNA interference response (negative control) or with siRNA specific for murine RIP1 
(RIP1 siRNA) and analyzed as in (d, e), except that CHX was omitted from treatment. Inset control Western blot for murine RIP1 to verify 
successful downregulation. Detection of actin served as a loading control. h, i Wild-type (WT) and RIP1-deficient (RIP1−/−) Jurkat cells were 
analyzed as in (d, e), except that 50 μM zVAD-fmk and 2 μg/ml CHX were used for treatment with TNF/zVAD/CHX. Inset control Western blot 
for human RIP1 or actin to verify presence or absence of endogenous human RIP1 and equal loading. p values in (h) calculated using Student’s t 
test for WT versus RIP−/− cells were <0.001 in all instances (except for 24 h of MNNG treatment). j RIP3-positive or -negative cells were treated 
with TNF for 24 h or with MNNG (or 25 mM MMS) for 16 h as in (b) with addition of 20 μM (NIH3T3) or 50 μM (293T, MCF-7, HeLa) 
zVAD-fmk and 1 ng/ml (293T) or 0.25 μg/ml (MCF-7, HeLa) CHX before loss of membrane integrity was determined flow-cytometrically. 
Controls were included to demonstrate that treatment with zVAD-fmk(/CHX) alone was not toxic. The presence or absence of RIP3 was verified 
by Western blots with antibodies specific for murine (L929, NIH3T3) or human RIP3 (HeLa, 293T, MCF-7). The specificity of the antibodies 
was confirmed with cell lysates containing overexpressed murine or human RIP3 (not shown). Equal loading was verified by detection of actin. 
k, l NIH3T3 cells naturally deficient for RIP3 or stably retransfected with wild-type or kinase-defective murine GFP-RIP3 (GFP-RIP3 WT, GFP-
RIP3 KD) were treated with MNNG or TNF/zVAD and analyzed as in (f, g). Inset control Western blot for murine RIP3 (top), GFP (middle) or 
actin (bottom) to verify expression of the constructs, absence of endogenous murine RIP3, and equal loading. A reduced amount of lysate from 
293T cells overexpressing untagged murine RIP3 was used as control (293T+). Asterisks nonspecific bands. p values in (k) calculated using Stu-
dent’s t test for GFP-RIP3 WT versus untransfected NIH3T3 cells were <0.001 for 0, 5 and 10 h of treatment with MNNG and 24 h of treatment 
with TNF/zVAD. m, n As part of the same experiment as shown in (f, g), NIH3T3 cells naturally expressing RIP3 were additionally nucleofected 
with siRNAs specific for murine RIP3 and analyzed as in (f, g). For clarity of presentation, the data are shown in new panels, but with the same 
negative control values as in (f, g). Inset control Western blot for downregulation of murine RIP3. Actin was detected as a loading control. Except 
for 24 h of MNNG treatment, p values in (m) calculated using Student’s t test for cells transfected with negative control siRNA versus RIP3 
siRNA were <0.01 (0 and 12 h of MNNG treatment) or <0.001 (all other time points). o, p Primary MEF or q, r primary lung fibroblasts (LF) 
from wild-type (WT) or RIP3-deficient (RIP3−/−) mice were analyzed as in (f, g). Insets control Western blots for murine RIP3 or actin to verify 
presence or absence of endogenous murine RIP3 and equal loading. s TNF-R1/TNF-R2 double-deficient murine fibroblasts (TNF-R1/2−/−) and 
TNF-R1/2−/−-fibroblasts stably re-expressing TNF-R1 (TNF-R1/2−/−TNF-R1) were analyzed as in (d). Inset control Western blot for expression 
or absence of TNF-R1. Actin was detected as a loading control. t L929Ts, L929ATCC and L929sA cells were treated with 100 ng/ml TNF for 
24 h or with MNNG (0.5 mM) or MMS (25 mM) for 15 min and further incubated for 16 h with fresh medium without MNNG or MMS, with 
or without addition of the radical scavenger BHA (150 μM, 2 h pretreatment). Subsequently, loss of membrane integrity was analyzed by flow 
cytometry
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pancreatitis. Inhibition of the PARP pathway has also dem-
onstrated benefit in chronic disease models, e.g., cardio-
vascular aging, atherosclerosis, and diabetic cardiovascular 
complications. Furthermore, the PARP pathway represents 
a promising target for treatment of autoimmune conditions, 
including type 1 diabetes, glomerulonephritis, multiple 
sclerosis, and rheumatoid arthritis [1, 25, 33].
In the model currently established for L929 cells 
(Fig. 6a), the PARP pathway represents an integral part of 
TNF-induced necroptosis [1, 15]. The results obtained in 
our study in multiple cell systems, however, clearly indi-
cate that this is not the case. Rather, TNF-induced necrop-
tosis and PARP-1-mediated necrosis apparently operate 
independently and represent separate routes to programmed 
necrosis. Of note, although our data show for the first time 
that RIP3 and, in extension of previous reports [14, 27], 
also RIP1 indeed do participate in the PARP pathway, our 
results nevertheless demonstrate that this contribution is 
cell type-specific and only of limited impact, in contrast 
to the ubiquitous, essential function of RIP1 and RIP3 in 
TNF-induced necroptosis. Most importantly, we have dem-
onstrated that any role of RIP1 or RIP3 in the PARP path-
way cannot depend on signals mediated by TNF-R1, and 
thus revalidated our concept of TNF-induced necroptosis 
and PARP-1-mediated necrosis as distinct and independ-
ent routes to programmed necrotic cell death. This revised 
model (Fig. 6b) is additionally corroborated by data from 
independent studies. Seok et al. [34] demonstrated that 
Fig. 4  continued
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JNK activation by DNA-damaging agents occurs in a TNF-
independent manner, although RIP1 is required. Two inde-
pendent studies [35, 36] failed to find an obligate role of 
JNK in TNF-induced cell death in multiple cell systems, 
despite their reported role in the PARP pathway [14]. Iden-
tical to our results, induction of necroptosis in L929 cells 
with TNF did not lead to detectable AIF release within 
12 h [37]. In Jurkat and BALB/c 3T3 cells, necroptotic cell 
death could not be blocked by small-molecule inhibition of 
factors such as calpains and PARP-1, or the downregula-
tion of AIF by RNA interference [38]. Inhibition of cath-
epsins B, L, H, or D as further components of the PARP 
pathway [13] failed to affect TNF-induced necroptosis in 
murine hepatocytes [39]. Conversely, necrostatin-1 did not 
protect murine hippocampal HT-22 cells against MNNG-
induced necrosis [40]. Andrabi et al. [41] independently 
found that necroptosis-resistant HeLa cells are still sensi-
tive to MNNG-induced necrosis, and the failure of BHA to 
protect against MNNG has been reported also for Chinese 
hamster V79 cells [42].
Notably, Jouan-Lanhouet et al. [43] have recently 
reported that TRAIL induces necroptosis at acidic extra-
cellular pH (pHe) involving RIP1/RIP3-dependent PARP-1 
activation, seeming to be at odds with our results at first 
glance. However, the same group has previously reported 
that in spite of a necrosis-like cell death morphology, cas-
pase activity is required for cell death in this system and 
that both zVAD-fmk and the caspase-8 inhibitor zIETD-
fmk fully block TRAIL-induced cell death at acidic pHe 
[44]. This dependence on caspases is however not consist-
ent with the molecular mechanisms described for necrop-
tosis [45] but rather points to a mode of cell death differ-
ent from TNF-induced necroptosis studied here, where we 
have never observed an inhibitory effect of zVAD-fmk in 
the many experiments where it was added. Therefore, an 
involvement of PARP-1 in the TRAIL-induced mode of 
cell death described by Jouan-Lanhouet is feasible based 
on the data presented in their study, but does not impli-
cate a similar role of PARP-1 in TNF-induced necroptosis 
as studied here. Also, such a role still would have to be 
Fig. 5  The PARP-1 inhibitor 3-AB does not counteract TNF-induced 
loss of membrane integrity and ATP depletion in L929 cells. a 
L929Ts, L929ATCC and L929sA cells were preincubated for 2 h with 
40 μM zVAD-fmk, 3 mM 3-AB, or a combination of both, and then 
treated with the indicated concentrations of TNF for 5 h before loss 
of membrane integrity was determined flow-cytometrically. b Cells 
were preincubated and treated with 3-AB and/or zVAD-fmk as in (a) 
and stimulated with 40 ng/ml TNF for 4 h before intracellular ATP 
levels were determined. c To verify the efficacy of 3-AB under the 
conditions used above, L929Ts, L929ATCC and L929sA cells were 
preincubated for 2 h with 40 μM zVAD-fmk, 3 mM 3-AB, or a com-
bination of both, and then with 0.5 mM MNNG for 16 h before ATP 
depletion was determined
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validated for true necroptosis induced by TRAIL, e.g., in 
the presence of zVAD-fmk, and at physiologic pHe (7.4). 
Moreover, the effects described in the study of Jouan-Lan-
houet et al. do not occur at physiologic pHe but are exclu-
sively limited to acidic conditions, again different from our 
observations for TNF-induced necroptosis. Finally, Jouan-
Lanhouet et al. [43] themselves demonstrate that their 
findings do not apply to necroptosis induced by either TNF 
or FasL, regardless of physiologic or acidic pHe, again 
suggesting that the conclusions from their study cannot be 
easily generalized for other death receptors or physiologic 
conditions.
Of particular importance, this study provides a first 
answer to the recently raised question whether there is 
one core program or several independent pathways of 
necrosis, with implications for the future development 
of necroptosis-inhibitory cytoprotective drugs as well as 
for the design of therapeutic strategies. The existence of 
several distinct pathways that trigger necrosis implies that 
an efficient protection requires their simultaneous inter-
ruption via combination therapies [1]. As a consequence 
of the results obtained in this study, we suggest that the 
simultaneous rather than the individual application of 
highly specific necroptosis and PARP-inhibitors (e.g., 
necrostatin and olaparib) may be the approach of choice 
for a future, improved treatment of necrosis-induced 
damage in diseases such as shock, stroke, or myocardial 
infarction.
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